Nasorinit (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine hydrochloride is a selective H1‑histamine receptor antagonist. By blocking these receptors, it prevents histamine‑mediated symptoms such as itching, sneezing and watery discharge, providing rapid relief of the allergic response in the nasal passages.

The dosage of Nasorinit is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and local labeling requirements. Patients should follow the prescriber’s instructions and the product’s package insert for the recommended number of sprays per day.

Safety in pregnancy and lactation has not been fully established. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Nasorinit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasorinit combines an antihistamine (azelastine) with a corticosteroid (fluticasone) in a single nasal spray, offering both rapid symptom relief and anti‑inflammatory control. This dual‑action approach can be more convenient than using separate antihistamine and steroid sprays, and may provide superior symptom control for many patients.

Nasorinit should be stored at ambient temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

Nasorinit is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is then repeated in the other nostril if required.

Serious risks, although rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes related to intra‑ocular pressure, and systemic effects from prolonged high‑dose corticosteroid exposure such as adrenal suppression. Patients should seek immediate medical attention if any of these occur.

Nasorinit should be avoided in individuals with known hypersensitivity to azelastine, fluticasone or any excipients in the formulation. It is also contraindicated in patients who have had recent nasal surgery or trauma until healing is complete, and in children below the age specified on the product label.